Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis

Study Overview
=================
Brief Summary
-----------------
Patients who carried primary or secondary myelofibrosis from Philadelphia negative MPNs (PMF/SMF) and who are treated or are about to be treated with pegylated-interferon (mostly α2a) are eligible to this prospective study. Biological and clinical parameters will be collected from the beginning of the drug use until last news. A non-opposition consent form need to be signed before entering this study.

Detailed Description
-----------------
In all centres interested, patients who were diagnosed for PMF/SMF can be treated with oral or sub-cutaneous drugs in order to reduce clinical symptoms and biological abnormalities belonging to these diseases. Pegylated-interferon is one of the better weapons that can be used in these cases. These treatments are well known and used from many years in french hematological centres. The investigators to collect clinical and biological data from patients treated with pegylated-interferon α2a (the most use) in case of PMF/SMF in order to assess efficacity and tolerance to this drug. The prescription of the product and the dose are under the responsibility of each practician. Clinical data collected: disease and patients characteristics at the time of diagnosis and at the beginning of the drug use, spleen and liver size, presence of constitutive symptoms, transfusion needs. Biological data collected: complete hemogram, CD34+ cells count, allele burden of JAK2V617F and calreticulin clones if DNA samples are collected. These data will be collected avery 3 months during the two first years and every 6 months after. The investigators also recorded adverse side effects if significative, the concomitant use of hematological drugs (cytoreductive treatments, ASE...), modalities of prescription of the drugs and the reason for stopping the drug and etiology of death if happened.

Official Title
-----------------
Etude de l'efficacité et de la tolérance de l'interféron-pégylé Dans Les myélofibroses

Conditions
-----------------
Myelofibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary or secondary Myelofibrosis Prescription of pegylated interferon α2a Age > 18 years-old Exclusion Criteria: Other MPNs treated with pegylated interferon α2a Patients treated for PMF or SMF but without pegylated interferon

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficiency of the interferon in Myelofibrosis | Evaluation on the presence or not of splenomegaly and physical signs or the normalization of blood counts. | Evaluation at 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of survival of patients with Myelofibrosis under interferon | Patients dead or alive at this time | Evaluation at 5 years | 
| Tolerance of Interferon | Presence or not of psychiatric symptoms, cramps, hepatitic abnormalities | Evaluation at 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
myelofibrosis, pegylated interferon